- Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies
- Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
- Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session
- Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024
- Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024
- Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference
- Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
- Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
More ▼
Key statistics
On Friday, Edgewise Therapeutics Inc (EWTX:NSQ) closed at 16.17, -21.85% below its 52-week high of 20.69, set on Feb 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.06 |
---|---|
High | 16.93 |
Low | 15.99 |
Bid | 15.42 |
Offer | 22.00 |
Previous close | 15.94 |
Average volume | 546.80k |
---|---|
Shares outstanding | 93.11m |
Free float | 92.70m |
P/E (TTM) | -- |
Market cap | 1.48bn USD |
EPS (TTM) | -1.57 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
More ▼